View the latest Galectin Therapeutics Corporate Presentation

A general overview of the company's activities and Clinical Phase studies with the Galectin-3 inhibitor GR-MD-02.

Supplemental presentation on GR-MD-02 for indication of NASH Cirrhosis

A detailed review of the results of the NASH-CX Clinical Trial.

Supplemental presentation on GR-MD-02 for Combination Cancer Immunotherapy

A detailed review of the use of GR-MD-02 in combination therapy with KEYTRUDA in advanced melanoma.

Galectin Therapeutics, Inc.

NASDAQ: GALT

Corporate Snapshot

Subscribe